Athersys (NASDAQ:ATHX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a research report released on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Shares of Athersys stock opened at $0.01 on Wednesday. The firm has a market capitalization of $345,626.40, a PE ratio of 0.00 and a beta of -0.90. The business’s 50-day moving average price is $0.01 and its 200-day moving average price is $0.07. Athersys has a 12 month low of $0.01 and a 12 month high of $1.99.

Institutional Investors Weigh In On Athersys

Institutional investors and hedge funds have recently bought and sold shares of the business. Private Advisor Group LLC purchased a new stake in Athersys in the 1st quarter worth approximately $27,000. BNP Paribas Arbitrage SA lifted its holdings in Athersys by 604.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 129,530 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 111,140 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in Athersys in the 4th quarter worth approximately $36,000. CIBC Asset Management Inc purchased a new stake in Athersys in the 1st quarter worth approximately $45,000. Finally, Jane Street Group LLC lifted its holdings in Athersys by 438.1% in the 2nd quarter. Jane Street Group LLC now owns 186,076 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 151,494 shares during the period. Hedge funds and other institutional investors own 19.35% of the company’s stock.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.